Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

202 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Initial properdin binding contributes to alternative pathway activation at the surface of viable and necrotic cells.
van Essen MF, Schlagwein N, van den Hoven EMP, van Gijlswijk-Janssen DJ, Lubbers R, van den Bos RM, van den Born J, Ruben JM, Trouw LA, van Kooten C; COMBAT consortium. van Essen MF, et al. Among authors: van den hoven emp, van gijlswijk janssen dj, van den born j, van den bos rm, van kooten c. Eur J Immunol. 2022 Apr;52(4):597-608. doi: 10.1002/eji.202149259. Epub 2022 Feb 17. Eur J Immunol. 2022. PMID: 35092629 Free PMC article.
Identification of tubular heparan sulfate as a docking platform for the alternative complement component properdin in proteinuric renal disease.
Zaferani A, Vivès RR, van der Pol P, Hakvoort JJ, Navis GJ, van Goor H, Daha MR, Lortat-Jacob H, Seelen MA, van den Born J. Zaferani A, et al. Among authors: van den born j, van goor h, van der pol p. J Biol Chem. 2011 Feb 18;286(7):5359-67. doi: 10.1074/jbc.M110.167825. Epub 2010 Dec 6. J Biol Chem. 2011. PMID: 21135110 Free PMC article.
MASP-2 Is a Heparin-Binding Protease; Identification of Blocking Oligosaccharides.
Talsma DT, Poppelaars F, Dam W, Meter-Arkema AH, Vivès RR, Gál P, Boons GJ, Chopra P, Naggi A, Seelen MA, Berger SP, Daha MR, Stegeman CA, van den Born J; COMBAT Consortium. Talsma DT, et al. Among authors: van den born j. Front Immunol. 2020 Apr 28;11:732. doi: 10.3389/fimmu.2020.00732. eCollection 2020. Front Immunol. 2020. PMID: 32425936 Free PMC article.
Weak Expression of Terminal Complement in Active Antibody-Mediated Rejection of the Kidney.
Tiller G, Lammerts RGM, Karijosemito JJ, Alkaff FF, Diepstra A, Pol RA, Meter-Arkema AH, Seelen MA, van den Heuvel MC, Hepkema BG, Daha MR, van den Born J, Berger SP. Tiller G, et al. Among authors: van den heuvel mc, van den born j. Front Immunol. 2022 Apr 13;13:845301. doi: 10.3389/fimmu.2022.845301. eCollection 2022. Front Immunol. 2022. PMID: 35493506 Free PMC article.
Lectin complement pathway gene profile of the donor and recipient does not influence graft outcome after kidney transplantation.
Damman J, Kok JL, Snieder H, Leuvenink HG, van Goor H, Hillebrands JL, van Dijk MC, Hepkema BG, Reznichenko A, van den Born J, de Borst MH, Bakker SJ, Navis GJ, Ploeg RJ, Seelen MA. Damman J, et al. Among authors: van den born j, van goor h, van dijk mc. Mol Immunol. 2012 Feb;50(1-2):1-8. doi: 10.1016/j.molimm.2011.11.009. Epub 2011 Dec 15. Mol Immunol. 2012. PMID: 22173059
Targeted inhibition of renal Rho kinase reduces macrophage infiltration and lymphangiogenesis in acute renal allograft rejection.
Poosti F, Yazdani S, Dolman ME, Kok RJ, Chen C, Ding G, Lacombe M, Prakash J, van den Born J, Hillebrands JL, van Goor H, de Borst MH. Poosti F, et al. Among authors: van den born j, van goor h. Eur J Pharmacol. 2012 Nov 5;694(1-3):111-9. doi: 10.1016/j.ejphar.2012.08.010. Epub 2012 Sep 3. Eur J Pharmacol. 2012. PMID: 22964464
202 results